On October 6, 2026, the company announced that its board approved a restructuring on October 2, 2026 while it conducts a process to explore strategic alternatives to maximize stockholder value. The restructuring includes the planned discontinuation ofClinical Trialsand further development of two allogeneic CAR-T …
Revenue was USD 18,440,210 against USD 16,965,658 a year earlier.Gross Profitwas USD 7,696,790 against USD 7,370,506, and total operating expenses were USD 8,889,932 against USD 8,012,907.
Cerenome is a U.S. healthcare company focused on central nervous system cancers through threeBusinessareas: precision diagnostics, targeted radiopharmaceutical therapeutics and proprietary data analytics. Effective August 3, 2026, it filed an amendment to change its name from Plus Therapeutics.
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead candidate, neflamapimod, is an oral small molecule that inhibits theAlphaisoform of p38 MAP kinase.
The filing says the company has been integrating a newly acquired international tradingBusinesswhile developing a new business strategy.
Chimera reports two segments, Investment Portfolio and Residential Origination. Management describes a platform that brings together mortgage origination through HomeXpress Mortgage, asset management through Palisade and securitization through a conduit called Prism Capital. TotalAssetswere USD 16,709,206 thousand at September 30, 2026, against USD 15,808,542 …
On June 29, 2026, the company changed its name from Atlantic International Corp to Circle8 Group Inc. It began trading under theNasdaqticker CIRC on July 2, 2026 and describes itself as a worldwide strategic staffing firm.
Revenue was USD 5,791,488 against USD 6,713,587. Total operating expenses were USD 2,909,850 against USD 3,966,227, and the loss from operations was USD 1,487,086 against USD 2,329,387. The net loss was USD 1,612,705 against USD 3,009,921, and the loss per share was USD 0.04 …
Cloudastructure describes itself as an innovator in cloud-native, AI-powered security solutions that deliver real-time situational awareness to enterprises.
Co-Diagnostics, a Utah corporation, develops, manufactures and sells reagents used for diagnostic tests that detect and analyze nucleic acid molecules, including DNA and RNA.